A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer.
Phase of Trial: Phase IV
Latest Information Update: 02 Sep 2016
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Roche
- 12 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Mar 2010 Planned number of patients changed from 20 to 60 as reported by ClinicalTrials.gov.